Observational studyMedicine2025
Factors influencing uptake of BRCA1/2 testing and contralateral prophylactic mastectomy among Chinese breast cancer patients.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Willingness of Chinese Breast Cancer Patients for Their Children to UndergoInternational journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenic mutations in breast cancer susceptibility gene 1/2 (BRCA1/2) are well established to increase the risk of breast cancer. However, few studies have examined the acceptance of genetic testing and contralateral prophylactic mastectomy (CPM) among Chinese breast cancer patients. This study aims to evaluate the knowledge and attitudes regarding genetic testing and risk management among Chinese women with breast cancer, and to identify factors associated with their intentions to pursue such management strategies. We conducted a prospective analysis using questionnaire-based surveys to assess attitudes toward BRCA1/2 genetic testing and the acceptance of CPM among 608 newly diagnosed breast cancer patients at Peking University International Hospital between May 2020 and May 2025. Multivariate analysis was performed to identify factors influencing these attitudes. Participants ranged from 22 to 87 years (mean ± standard deviation: 51.8 ± 12.3 years); 589 (96.9%) were married and 546 (89.8%) had children. Overall, 325 patients (53.5%) expressed willingness to undergo BRCA1/2 genetic testing, whereas only 191 (31.4%) would consider CPM if carrying a pathogenic BRCA1/2 mutation. Multivariate analysis identified age (odds ratio [OR] = 0.978, 95% confidence interval [CI]: 0.963-0.992, P = .003), prior counseling from healthcare professionals on genetic risk (OR = 2.358, 95% CI: 1.505-3.694, P = .000), and awareness of the "Angelina Jolie effect" (OR = 1.857, 95% CI: 1.277-2.699, P = .001) as independent predictors of willingness to undergo genetic testing. For CPM, independent predictors included age (OR = 0.983, 95% CI: 0.968-0.999, P = .039) and prior counseling on genetic risk (OR = 1.576, 95% CI: 1.035-2.401, P = .034). Professional genetic counseling and celebrity influence are key determinants of breast cancer patients' awareness of BRCA testing and uptake of risk-reducing surgery, underscoring the need for clinicians to integrate these factors into patient-centered decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.